- Home
- Â /Â Revance Therapeutics
Revance Therapeutics
Stock Price
$5.9
2024-10-29
Market Capitalization
$615.7 M
2024-10-29
Revenue
$234 M
FY, 2023
Revance Therapeutics Summary
Company Summary
- Overview
- Revance Therapeutics is a biotechnology company that develops and commercializes aesthetic and therapeutic offerings. It focuses on the manufacture of neuromodulators for treatment of various health conditions.
- Type
- Public
- Status
- Active
- Founded
- 2002
- HQ
- Nashville, TN, US | view all locations
- Website
- https://www.revance.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Dwight Moxie, Senior Vice President, General Counsel & Corporate Secretary
Tobin Schilke, Chief Financial Officer
David A. Hollander, Chief Medical Officer
Operating MetricsView all
Products and Services
4
FY, 2022
Facility Space Leased, sq. ft.
88.5K
117.7%
FY, 2022
LocationsView all
4 locations detected
Nashville, TNÂ HQ
United States
1222 Demonbreun St Suite 2000
Irvine, CA
United States
18201 Von Karman Ave #120
Newark, CA
United States
7555 Gateway Blvd
Pleasanton, CA
United States
6220 Stoneridge Mall Rd 3rd Floor
Revance Therapeutics Financials
Summary Financials
- Revenue (Q3, 2024)
- $59.9M
- Net income (Q3, 2024)
- ($38.1M)
- Cash (Q3, 2024)
- $58.6M
- EBIT (Q3, 2024)
- ($32.3M)
- Enterprise value
- $988.3M